<!DOCTYPE HTML>
<html>
	<head>
		<title>Treating Fragile X Syndrome with CRISPR/Cas9</title>
		<link href="https://fonts.googleapis.com/css?family=Poppins:300,500,700" rel="stylesheet">
		<link href="https://fonts.googleapis.com/css?family=Roboto+Condensed:300,500,700" rel="stylesheet">
		<style>
			* {
				margin: 0;
				padding: 0;
				-webkit-box-sizing: border-box;
				-moz-box-sizing: border-box;
				box-sizing: border-box;
			}

			body {
				background: #0a1612;
			}

			header, section {
				margin: auto;
			}

			header {
				width: 1250px;
				padding: 7.5rem 0 3rem;
			}

			h1 {
				font: 500 5rem/100% Poppins, Arial, sans-serif;
				color: #fff;
				letter-spacing: -2px;
				margin-bottom: 3rem;
			}

			h1 strong {
				font-weight: 700;
				background: #c55360;
				padding: 0 .75rem;
			}

			h1:first-child {
				text-align: left;
			}

			h1:nth-child(2) {
				text-align: right;
			}

			h3 {
				font: 300 1rem/125% Arial;
				letter-spacing: -.5px;
				color: #ccc;
				width: 80%;
				margin: 0 auto 1rem;
			}

			section {
				width: 1100px;
			}

			p {
				font: 300 1.75rem Poppins;
				color: #fff;
				margin: 2rem 0;
			}
		</style>
	</head>

	<body>
		<header>
			<h1>
				Treating
				<strong>Fragile X Syndrome</strong>
			</h1>
			<h1>
				With
				<strong>CRISPR/Cas9</strong>
			</h1>

			<br>

			<h3>X. Shawn Liu<sup>1</sup>, Hao Wu<sup>1,3</sup>, Marine Krzisch<sup>1</sup>, Xuebing Wu<sup>1</sup>, John Graef<sup>3</sup>, Julien Muffat<sup>1</sup>, Denes Hnisz<sup>1</sup>, Charles H. Li<sup>1,2</sup>, Bingbing Yuan<sup>1</sup>, Chuanyun Xu<sup>1,4</sup>, Yun Li<sup>1</sup>, Dan Vershkov<sup>5</sup>, Angela Cacace<sup>3</sup>, Richard A. Young<sup>1,2</sup>, Rudolf Jaenisch<sup>1,2,6</sup></h3>

			<h3>1. <b>Whitehead Institute for Biomedical Research</b>, Cambridge, MA 02142, USA; 2. Department of Biology, <b>Massachusetts Institute of Technology</b>, Cambridge, MA 02142, USA; 3. <b>Fulcrum Therapeutics</b>, One Kendall Square, Biney St b7102, Cambridge, MA 02139, USA; 4. Present address: Department of Biology, <b>Stanford University</b>, Stanford, CA 94305, USA; 5. <b>The Hebrew University of Jerusalem</b>, Edmond J. Safra Campus, Givat Ram, Jerusalem 91904, Israel</h3>
		</header>
		
		<section>
			<p>Throughout the world, <b>1 in 3600 males</b> and <b>1 in 4000 females</b> suffer from <b>fragile X syndrome (FXS)</b>, an inherited developmental disorder.</p>

			<p>Symptoms range from <b>intellectual disability</b> and <b>aggressive, hyperactive behavior</b> to <b>seizues</b> and <b>physical abnormalities such as a long face, large forehead and ears, and flat feet</b>.</p>

			<p>FXS occurs when the <b><i>FMR1</i></b> gene, located at the end of the X chromosome, is turned off.</p>

			<p>Healthy people have up to 55 <b>repeats of “CGG”</b> at the promoter of their FMR1 gene, all of which are <b>unmethylated</b>—these nucleotides don't have methyl groups attached.</p>

			<p><b>Carriers</b> of the FXS premutation have about 55 to 200 unmethylated CGGs.

			<p>People with the full mutation have over 200 CGG repeats, leading to methylation of the promoter region, which silences the gene.</p>

			<p>Recently, researchers hypothesized that they could use <b>CRISPR/Cas9, a gene editing technology</b>, to demethylate that region, reactivate FMR1, and <b>cure fragile X syndrome in mice</b>.</p>
		</section>
	</body>
</html>